Non-Hodgkin Lymphoma News

• Childhood Cancer on the Rise in Europe
  Reuters Health Information, August 2018
• Routine Lab Testing of Little Value in Surveillance of Aggressive Lymphoma Routine laboratory testing has limited value in the surveillance of aggressive lymphoma in asymptomatic patients in complete remission, researchers from Australia report.
  Reuters Health Information, August 2018
• First Trial Alleging Monsanto's Roundup Causes Cancer Goes to Jury A trial in which a school groundskeeper alleged that his use of Monsanto's Roundup weed killer caused his terminal cancer will go to a California jury after lawyers for both sides delivered their closing arguments on Tuesday.
  Reuters Health Information, August 2018
• Cancer Care for Adolescents Costs More in Pediatric Institutions Costs of cancer care for adolescents are significantly higher in pediatric institutions than in adult institutions, researchers from Canada report.
  Reuters Health Information, July 2018
• Combo of RT and Chemoimmunotherapy: Best for Early FL? For early follicular lymphoma, a randomized study finds that the combination of radiation therapy and chemoimmunotherapy works better than radiotherapy alone. Will this change practice?
  Medscape Medical News, July 2018
• Lower Risk Of Follicular Lymphoma Transformation With Rituximab The risk of transformation of follicular lymphoma is significantly lower with rituximab treatment, according to results from the Aristotle study.
  Reuters Health Information, July 2018
• U.S. Judge Allows Lawsuits Over Monsanto's Roundup to Proceed to Trial A federal U.S. judge on Tuesday allowed hundreds of lawsuits alleging that Monsanto Co's glyphosate-containing weed-killer Roundup causes cancer to proceed to trial, finding that there was sufficient evidence for a jury to hear the cases.
  Reuters Health Information, July 2018
• CTI Biopharma's Cancer Drug Fails Late-Stage Trial, Shares Tumble
  Reuters Health Information, July 2018
• EHA 2018First-in-Class Drug Against CD79b Improves Survival in DLBCL The first-in-class antibody-drug conjugate polatuzumab vedotin significantly improved response and overall survival in relapsed or refractory diffuse large B-cell lymphoma.
  Medscape Medical News, June 2018
• EHA 2018Novel Nonchemo Combo (Len-R) Effective in Follicular Lymphoma A novel chemotherapy-free regimen containing lenalidomide and rituximab showed similar efficacy but less toxicity than the standard combination of rituximab and chemotherapy in the RELEVANCE trial.
  Medscape Medical News, June 2018
• JAK1/2 Inhibitors Linked to Lymphoma Risk in Myelofibrosis New data show that the use of JAK1/2 inhibitors, the only FDA-approved therapies for myeloproliferative neoplasms, is associated with a risk for lymphoma.
  Medscape Medical News, June 2018
• EHA 2018Vitamin D Deficiency and Reduced Hodgkin Lymphoma Survival A large study has found that patients with Hodgkin lymphoma who showed baseline deficiencies in vitamin D had significantly shorter progression-free and overall survival.
  Medscape Medical News, June 2018
• Helping Cancer Patients to Understand New 'Right-to-Try' Law The new measure should have been called the 'right-to-ask' law, as the decision about whether to provide experimental drugs still rests with pharma companies, says one expert.
  Medscape Medical News, June 2018
• ASCO 2018Emojis Help Cancer Patients Report Symptoms, QoL Wearable technologies and emoji mood scales could be the future of patient-reported outcome assessment in cancer patients, suggested a US study presented at the world's largest cancer meeting.
  Medscape Medical News, June 2018
• ASCO 2018Combo Improves Outcomes in Waldenstrom's Macroglobulinema The combination of ibrutinib plus rituximab dramatically extends progression-free survival over rituximab alone, regardless of treatment or mutational status.
  Medscape Medical News, June 2018
• ASCO 2018Wider Concerns of Older Cancer Patients 'Need Addressing' Age-related concerns of older cancer patients are more likely to be discussed and acted on if oncologists are given results of geriatric assessments, say US scientists who call for their wider use.
  Medscape Medical News, June 2018
• IWMF 2018New Drugs Poised to Expand Treatment Horizons in WM New drug combinations and pathways continue to be mined in an effort to expand treatment horizons for control of a rare lymphoma and extend quality of life for patients over many years to come.
  Medscape Medical News, May 2018
• IWMF 2018Patience Needed: WM Is Incurable, but Survival Is Long Management of the rare lymphoma Waldenstrom's macroglobulinemia (WM) takes patience and practice to maximize longevity and keep symptoms at bay over the long haul.
  Medscape Medical News, May 2018
• Non-AIDS Cancers Expected to Dominate in HIV-infected Adults by 2030
  Reuters Health Information, May 2018
• Bortezomib-induced Neuropathic Pain a Consequence of Sphingolipid-metabolism Dysregulation
  Reuters Health Information, May 2018